ABSTRACT
Resumo A deficiência de ferro (DF) ou ferropenia é uma importante comorbidade na insuficiência cardíaca com fração de ejeção reduzida (ICFER) estável, e muito prevalente tanto nos anêmicos como não anêmicos. A ferropenia na ICFER deve ser pesquisada por meio da coleta de saturação de transferrina e ferritina. Há dois tipos de ferropenia na IC: absoluta, em que as reservas de ferro estão depletadas; e funcional, onde o suprimento de ferro é inadequado apesar das reservas normais. A ferropenia está associada com pior classe funcional e maior risco de morte em pacientes com ICFER, e evidências científicas apontam melhora de sintomas e de qualidade de vida desses pacientes com tratamento com ferro parenteral na forma de carboximaltose férrica. O ferro exerce funções imprescindíveis como o transporte (hemoglobina) e armazenamento (mioglobina) de oxigênio, além de ser fundamental para o funcionamento das mitocôndrias, constituídas de proteínas à base de ferro, e local de geração de energia na cadeia respiratória pelo metabolismo oxidativo. A geração insuficiente e utilização anormal de ferro nas células musculares esquelética e cardíaca contribuem para a fisiopatologia da IC. A presente revisão tem o objetivo de aprofundar o conhecimento a respeito da fisiopatologia da ferropenia na ICFER, abordar as ferramentas disponíveis para o diagnóstico e discutir sobre a evidência científica existente de reposição de ferro.
Abstract Iron deficiency (ID) is an important comorbidity in heart failure with reduced ejection (HFrEF) and is highly prevalent in both anemic and non-anemic patients. In HFrEF, iron deficiency should be investigated by measurements of transferrin saturation and ferritin. There are two types of ID: absolute deficiency, with depletion of iron stores; and functional ID, where iron supply is not sufficient despite normal stores. ID is associated with worse functional class and higher risk of death in patients with HFrEF, and scientific evidence has indicated improvement of symptoms and quality of life of these patients with treatment with parenteral iron in the form of ferric carboxymaltose. Iron plays vital roles such as oxygen transportation (hemoglobin) and storage (myoblogin), and is crucial for adequate functioning of mitochondria, which are composed of iron-based proteins and the place of energy generation by oxidative metabolism at the electron transport chain. An insufficient generation and abnormal uptake of iron by skeletal and cardiac muscle cells contribute to the pathophysiology of HF. The present review aims to increase the knowledge of the pathophysiology of ID in HFrEF, and to address available tools for its diagnosis and current scientific evidence on iron replacement therapy.
Subject(s)
Humans , Anemia, Iron-Deficiency/complications , Anemia, Iron-Deficiency/diagnosis , Anemia, Iron-Deficiency/therapy , Heart Failure/complications , Heart Failure/diagnosis , Heart Failure/therapy , Quality of Life , Stroke Volume , FerritinsABSTRACT
Introducción: La falla cardiaca es una enfermedad de alta prevalencia mundial y de gran interés para la salud pública. En Colombia constituye una de las principales causas de mortalidad de origen cardiovascular, por lo cual es importante determinar los factores de riesgo asociados con la mortalidad intrahospitalaria en estos pacientes. Materiales y métodos: Estudio de cohorte retrospectiva que incluyó a 260 pacientes con diagnóstico de falla cardiaca aguda atendidos en el Hospital Universitario San Rafael de Tunja (Colombia) entre enero de 2019 y enero de 2022. Con un análisis univariado y bivariado se construyó un modelo de regresión de Cox para determinar los factores asociados con mortalidad intrahospitalaria, y como desenlaces secundarios se determinó la incidencia de mortalidad intrahospitalaria a 10 días, el reingreso y el tiempo de estancia hospitalaria. Resultados: La incidencia de mortalidad intrahospitalaria a los 10 días fue del 10 %, el reingreso hospitalario se presentó en el 21,2 % de los pacientes, la media de estancia hospitalaria fue de 9,31 días. Los factores de riesgo para mortalidad intrahospitalaria estadísticamente significativos fueron la clasificación clínica de Stevenson C o L (HR: 3,2; IC: 1,12-9,39; p = 0,03) y la clase funcional del paciente a su ingreso NYHA III o IV (HR: 2,76; IC: 1,02-7,53; p = 0,04). Conclusiones: La clasificación clínica de Stevenson C o L y la clase funcional según NYHA III o IV demostraron ser factores de riesgo independientes de mortalidad intrahospitalaria. Se sugiere identificar tempranamente a estos pacientes, ya que podría asegurar una mayor supervivencia
Introduction: Heart failure is an illness of high prevalence at world level, and therefore one of great interest for public health. In Colombia, it is one of the leading causes of death from cardiovascular cause. For this reason, it is important to determine the risk factors associated to intrahospital morta-lity in these patients. Materials and methods: Retrospective cohort study that included 260 patients diagnosed with acute heart failure treated in San Rafael University Hospital in Tunja between January 2019 and January 2022. A univariate and a bivariate analysis were carried out calculating Hazard Ratio and p values. With these results, a Cox regression model was made to determine the associated factors in intrahos-pital mortality; in addition, the incidence of intrahospital mortality 10 days after admission; readmis-sions; and length of hospital stay were determined as secondary outcomes. Results: The incidence of intrahospital mortality 10 days after admission was of 10%; hospital read-missions occurred for 21.2% of the patients; the mean in hospital stay was of 9.31 days; the statis-tically significant risk factors for intrahospital mortality were Stevenson's clinical classification C or L (HR: 3.2; IC: 1.12-9.39; p = 0.03] and the patient's functional class at the time of admission NYHA III or IV (HR: 2.76; IC: 1.02-7.53; p = 0.04]. Conclusion: Stevenson's clinical classification C or L and the functional class NYHA III or IV emerge as independent risk factors for intrahospital mortality. Early identification of these patients is suggested for an increased rate of survival.
Introdução: a insuficiência cardíaca é uma doença de elevada prevalência em todo o mundo e que suscita grades preocupações em termos de saúde pública. Na Colômbia, esta é uma das principais causas de mortalidade cardiovascular, pelo que é importante determinar os fatores de risco associados à mortalidade intra-hospitalar nestes pacientes. Materiais e métodos: Estudo retrospectivo que inclui 260 pacientes com diagnostico de insuficiência cardíaca aguda tratados no Hospital Universitário San Rafael da cidade de Tunja (Colômbia) entre janeiro de 2019 e janeiro de 2022. Foi construído um modelo de regressão de Cox utilizando análises univariada e bivariada para determinar os fatores associados à mortalidade intra-hospitalar. A inci-dência de mortalidade intra-hospitalar aos 10 dias, a readmissão e a duração do internamento foram determinados como resultados secundários. Resultados: A incidência de mortalidade intra-hospitalar aos 10 dias foi de 10%, a readmissão ocorreu em 21,2% dos pacientes e o tempo médio de internamento foi de 9,31 dias. Os fatores de risco estatis-ticamente significativos para a mortalidade intra-hospitalar foram a classificação clínica de Stevenson C ou L (HR: 3,2; IC: 1,12-9,39; p = 0,03) e a classe funcional do paciente na admissão NYHA III ou IV (HR: 2,76; IC: 1,02-7,53; p = 0,04). Conclusões: A classificação clínica C ou L de Stevenson e a classe funcional III ou IV da NYHA provaram ser fatores de risco independentes para a mortalidade intra-hospitalar. A identificação precoce destes pacientes é sugerida, uma vez que pode assegurar uma sobrevivência mais longa
Subject(s)
Heart Failure , Cardiovascular Diseases , Hospital Mortality , Heart Failure, Diastolic , Heart Failure, SystolicABSTRACT
Objective To investigate the prevalence and prognostic value of anemia in male and female patients with chronic systolic heart failure (CSHF).Methods Data of in-hospital patients with CSHF were investigated between 2000 and 2010 from 12 hospitals in Hubei Province.Patients were divided into normal hemoglobin (Hb) group,mild anemia group,moderate anemia group,severe and extreme anemia group.According to age,body mass index (BMI) and correction of glomerular filtration rate (GFRc),patients were divided into several subgroups,respectively.Multivariate logistic regression was performed to determinate the associated factors with anemia.Kaplan-Meier curve was performed to evaluate the difference in all-cause mortality in male and female patients with anemia.Univariate and multivariate Cox proportion hazard analysis was performed to determinate the risk of all-cause mortality among different anemia group in male and female patients.Results A total of 16681 patients were enrolled.Anemia accounted for 23.79％ and 27.29％,separately,in male and female patients with CSHF.BMI and GFRc were related to anemia in both male and female patients with CSHF,while only age was related to anemia for female patients with CSHF.The hazard ratio of all-cause mortality was 1.08 (P ＜ 0.01),1.13 (P ＜ 0.O1) and 1.02 (P =0.74),respectively,for all,male and female anemia patients with CSHF,compared to normal Hb group.Compared to normal Hb group,the hazard ratio of mild anemia group,moderate anemia group,severe and extreme anemia group was 1.05 (P =0.14),1.20 (P ＜0.01) and 1.36 (P ＜0.01),respectively,for all CSHF patients;1.11 (P ＜ 0.01),1.35 (P ＜ 0.01) and 1.37 (P ＜ 0.01),respectively,for male;0.96 (P=0.48),1.08 (P=0.40) and3.47 (P＜0.01),respectively,for female.Conclusions Compared to male,female patients suffer higher prevalence of anemia in patients with CSHF.There is a significant difference in risk factors and prognosis of anemia between male and female patients with CSHF.
ABSTRACT
Objective:To observe therapeutic effect of lyophilized recombinant human brain natriuretic peptide (Lrh-BNP)on stress cardiomyopathy (SCM)complicated acute bump failure.Methods:A total of 23 patients with SCM complicated acute bump failure were randomly divided into routine treatment group (n=10,received routine treatment)and Lrh-BNP group (n=13,received Lrh-BNP based on routine treatment).Clinical symptoms and signs,cardiac function :left ventricular ejection fraction (LVEF),stroke volume (SV),cardiac index (CI),peak early diastolic velocity/peak late diastolic velocity (E/A)assessed by echocardiography before and after treatment, and total effective rate were compared between two group.Results:Total effective rate of Lrh-BNP group was sig- nificantly higher than that of routine treatment group (92.3% vs.80.0% ,P0.05 all);after treatment,com- pared with routine treatment group,there were significant rise in LVEF [(50.2±16.3)% vs.(59.4±14.1)%],SV [(39.5±10.4)ml vs.(48.3±12.5)ml],CI [(3.7±1.1)L min-1 m-2 vs.(4.6±1.4)L min-1 m-2 ]and E/A [(1.0±0.5)vs.(1.3±0.7)]in Lrh-BNP group,P<0.05 all.Conclusion:Lrh-BNP possesses significant thera- peutic effect on stress cardiomyopathy complicated acute left heart failure.
ABSTRACT
Objective To investigate the treatment of chronic heart failure in two communities in Pudong and find the deficiency of standardized treatment in community hospital.Methods A retrospective study of all the inpatient,family bed and outpatient with heart failure who visit Hudong and Lujiazui community health Service center was conducted from March 2012 to March 2015 retrospectively.General situation(gender,age,smoking history,drinking history,daily salt intake,concomitant disease),etiology and if have the acute heart failure onset in half a year and what are the incentives,drug treatment and treatment of concomitant hypertension and diabetes mellitus were analyzed by face to face follow up.Results The study included 300 patients,average age was (58 ± 10) years.Daily salt intake of 55.0％ (165/300)patients was more than 9 g.Coronary heart disease (45.7 ％,137/300),hypertension (30.7％,92/300)and cardiomyopathy (9.0％,27/300)were the chief heart failure etiology.59.3％ (178/300) patients had acute heart failure in half a year.Acute blood pressure(20.8％,37/178),transfusion too fast or too much and infection(14.6％,26/178) were the chief incentives leading to acute heart failure.83.3％ (250/300)patients used ACEI/ARB,but only 32.0％ (80/250) of them applied the target dose.53.7％ (161/300)patients used beta blockers and 98.1％ (158/161) of them could not reach the target dose.Tartaric acid metoprolol (51.6％,83/161),peso parlour (18.6％,30/161) and carvedilol (14.9％,24/161) were commonly used drug in clinic.76.6％ (230/300)patients had hypertension and blood pressure was controlled in 82.2％ (189/230) of them successfully.44.0％ (132/300) patients had diabetes mellitus and glycosylated hemoglobin (HbA1c) was controlled from 7 ％ to 8 ％ in 23.5 ％ (31/132) of them.Conclusion In the community treatment of heart failure,the drugs recommended by guidelines were low usage and achieved the target dose rarely.Treatment of concomitant diseases was not good.The knowledge of new progress was not enough.
ABSTRACT
PURPOSE: To evaluate whether post-hemorrhagic shock mesenteric lymph (PSML) is involved in cardiac dysfunction induced by hemorrhagic shock. METHODS: The hemorrhagic shock model (40±2 mmHg, 3h) was established in rats of the shock and shock+drainage groups; and PSML drainage was performed from hypotension 1-3h in the shock+drainage rats. Then, the isolated hearts were obtained from the rats for the examination of cardiac function with Langendorff system. Subsequently, the isolated hearts were obtained from normal rats and perfused with PSML or Krebs-Henseleit solution, and the changes of cardiac function were observed. RESULTS: The left ventricular systolic pressure (LVSP) and the maximal rates of LV developed pressure (LVDP) rise and fall (±dP/dt max) in the shock and shock+drainage groups were lower than that of the sham group; otherwise, these indices in the shock+drainage group were higher compared to the shock group. In addition, after isolated hearts obtained from normal rats perfusing with PSML, these cardiac function indices were gradual decline along with the extension of time, such as heart rate, LVSP, ±dP/dt max, etc. CONCLUSION: Post-hemorrhagic shock mesenteric lymph is an important contributor to cardiac dysfunction following hemorrhagic shock. .
Subject(s)
Animals , Male , Heart Diseases/etiology , Heart Diseases/physiopathology , Lymph/physiology , Mesentery/physiopathology , Shock, Hemorrhagic/complications , Shock, Hemorrhagic/physiopathology , Disease Models, Animal , Drainage/methods , Glucose , Heart Rate/physiology , Heart Ventricles/physiopathology , Mesentery/pathology , Random Allocation , Rats, Wistar , Reference Values , Time Factors , Tromethamine , Ventricular Pressure/physiologyABSTRACT
Objective To analyze the differences in clinical characteristics and risk factors in patients with diastolic heart failure and systolic heart failure. Methods A total of 2 088 patients with heart failure were divided into two groups, diastolic heart failure group (EF≥0.45,n=1 356) and systolic heart failure group (EF<0.45,n=732), according to ejection fraction (EF). The clinical features and related factors affecting the two types of heart failure were compared between two groups. Results There were higher age, higher proportion of women and higher proportion of hypertensive patients in dia?stolic heart failure group than those of systolic heart failure group, but lower rates of hypoalbuminemia, anemia, renal insuffi?ciency and hyperuricimia. There was higher incidence of functional class I and II in diastolic heart failure group. And com?pared with systolic heart failure group, there were higher levels of systolic blood pressure, albumin, prealbumin, cholesterol, sodium and serum chloride in diastolic heart failure group, but lower levels of heart rates, creatinine, blood uric acid, potassi?um and brain natriuretic peptide. Compared with systolic heart failure group, there were lower left ventricular end diastolic volume (LVEDV) and left ventricular end systolic volume (LVESV) in diastolic heart failure group. And there were lower RAS blocker andβ-blocker usage, higher statin usage in diastolic heart failure group. Logistic regression analysis showed that gender and hypertension were significantly correlated with diastolic heart failure, and hypoalbuminemia and hyper?uricimia were significantly correlated with systolic heart failure. Conclusion Our results show that there are differences in clinical features and risk factors in patients with diastolic heart failure and systolic heart failure. We should take the differ?ent treatment and prevention programs for the two kinds of heart failures.
ABSTRACT
Objective To explore the predictive value of plasma catestatin (CST ) and its influence factors for prognosis of patients with chronic systolic heart failure .Methods In a retrospective study ,the clinical data of 352 chronic systolic heart failure patients were collected from our hospital 2009 to 2013 .The patients were categorized into 4 groups (n= 88) according to CST (ng/L) quartile :≤ 60 .24 ,60 .25 - 76 .57 ,76 .58 - 86 .33 and ≥ 86 .34 ng/L .Blood pressure ,heart function ,blood biochemical index and renal function were compared among groups as well as the correlation with CST by Spearman correlation .According to the survival situation of follow‐up ,the patients were assigned into death and survival groups .The predictive value of CST for the prognosis of chronic systolic heart failure patients were analyzed by univariate and multivariate Cox survival analysis .Results Age ,sex ,body mass index ,red blood cell count ,red blood cell volume ,hemoglobin ,albumin ,total bilirubin ,serum creatinine ,blood urea nitrogen ,u‐ric acid and pathogeny among 4 groups had no statistical significance (P> 0 .05) .Patients with higher CST levels were more likely to had higher NYHA classification ,systolic pressure ,diastolic pressure ,high sensitivity C‐reactive protein (hs‐CRP) ,plasma N‐ter‐minal proBNP (NT‐proBNP ) ,left ventricular end‐diastolic diameter (LVEDD ) and right ventricular end‐diastolic diameter (RVEDD) ,and had a lower left ventricular ejection fraction (LVEF) (all P< 0 .05) .The CST was positively correlated with hs‐CRP ,NT‐proBNP ,LVEDD and RVEDD (r = 0 .452 ,0 .571 ,0 .536 ,0 .473) and negatively correlated with LVEF (r = - 0 .357) . Taken CST ≤ 60 .24 ng/L for reference ,the risks of death for groups of 60 .25 - 76 .57 ,76 .58 - 86 .33 and ≥ 86 .34 ng/L increased by 1 .471 ,1 .767 and 7 .822 ,respectively .The Cox survival analysis showed that NYHA classification ,LVEF ,cardiac arrhythmia , atrial enlargement ,heart failure history and CST were independent prognostic factors .Conclusion The mortality of patients with chronic systolic heart failure was associated with plasma CST .Elevated CST increased total mortality risk and were independent prognostic factors of these patients ,but the evaluation of the prognostic value of CST etiology factors should be considered .
ABSTRACT
Fundamento: la insuficiencia cardíaca sistólica (ICS) genera un aumento del estrés oxidativo que podría explicar un riesgo aumentado de aterosclerosis. Sin embargo, se desconoce si la prevalencia de ateromatosis carotídea es mayor en pacientes con disfunción sistólica del ventrículo izquierdo de etiología no isquémica respecto de la población general. El tratamiento con estatinas en la insuficiencia cardíaca (IC) es discutido, si bien existe evidencia de que algunos grupos podrían beneficiarse de estas. Conocer si pacientes con ICS de etiología no isquémica presentan mayor ateromatosis permitiría reconocer un subgrupo de pacientes que podrían beneficiarse de estrategias de tratamiento específicas Objetivo: determinar si la prevalencia de placas de ateroma carotídea en pacientes con ICS isquémica, no isquémica y en sujetos asintomáticos sin ICS y similar exposición a factores de riesgo tradicionales presenta diferencias. Método: se incluyeron (1) pacientes con ICS isquémica (grupo 1, G1; n=39; edad: 65±8 años; 67% hombres), (2) ICS no isquémica (grupo 2, G2; n=23; edad: 62±12, 78% hombres) y (3) un grupo control (grupo 3, G3; n=199; edad 58±9, 75% hombres) de sujetos con características similares a las del G2 (edad, sexo, factores de riesgo CV), pero sin IC. Se determinó presencia de placa de ateroma carotídea por ultrasonido. Se analizó prevalencia de placa en relación con el antecedente de dislipemia, tratamiento con estatinas y nivel objetivo de lipoproteínas de baja densidad (LDL) en sangre. Resultado: la prevalencia de placa de ateroma carotídea en G1 fue de 87% (intervalo de confianza del 95% [IC95%]: 76%-98%), en G2 de 61% (IC95%: 41%-81%) y en G3 37% (IC95%: 30%-44%) (p<0,05). La indicación de estatinas en el G2 se limitó a pacientes con dislipemia (65%). El 22% de los pacientes del G2 con placa no recibía estatinas. El 26% de los pacientes del G1 alcanza LDL objetivo (LDL<70mg/dL). En el G2 se logró LDL objetivo en el 40% (LDL < 100 mg/dL). Si el LDL objetivo es < 70 mg/dL, en pacientes con IC y ateromatosis el objetivo se cumple en el 25%. Conclusión: la prevalencia de ateromatosis carotídea en pacientes con ICS es elevada, incluso en pacientes con ICS de etiología no isquémica, habiendo en esta una prevalencia mayor que en la de sujetos sin IC, con similar prevalencia de factores de riesgo tradicionales. En la mayoría de los pacientes con IC no se alcanzan niveles de LDL objetivo.
Background: systolic heart failure (SHF) is associated with an increased oxidative stress which may be related with an increased risk of atherosclerosis; but it is unknown if carotid atherosclerosis is more frequent in patients with SHF of non-ischemic etiology than general population. Statins treatment in heart failure is discussed, although some groups may benefit from them. Identification of patients with SHF with non-ischemic etiology and atherosclerosis, would recognize a sub group of patients who can benefit from specific treatment strategies. Objective: to compare the prevalence of carotid plaques in patients with ischemic SHF, non-ischemic SHF and patients without HF or systolic dysfunction and similar cardiovascular risk factors. Method: thirty nine patients with ischemic SHF (Group 1, G1, age: 65±8 years; 67% men), 23 with non-ischemic SHF (Group 2, G2, age: 62±12, 78% men) were included. A control group with 199 patients (Group 3, G3; age 58±9 years, 75% men) with similar characteristics to G2 (age, sex, CV risk factors) was selected. Ultrasound was used to determine the presence of atherosclerotic carotid plaque. We defined prevalence of plaque in relation to the history of dyslipidemia, treatment with statins and low density lipoproteins (LDL) target level. Results: the prevalence of carotid plaque was: G1:87% (95% confidence interval (CI95%): 76-98%); G2:61% (CI95%:41-81%) and G3:37% (CI95%:30-44%) (p<0,05). Statins indication in G2 was limited to patients with dyslipidemia (65%). Twenty two % of patients in G2 with plaque were not receiving statins. Twenty six % of patients in G1 reached target LDL (LDL 70mg/dL); 40% in G2 reached LDL target level (LDL 100mg/dL). If LDL target level were 70 mg/dL in patients with heart failure and atherosclerosis, the objective was met in 25%. Conclusion: the prevalence of atherosclerotic carotid plaque is high in patients with SHF regardless etiology and it is higher than subjects with similar CV risk factors without SHF. Target LDL levels for treatment are not reached in most patients with SHF.
ABSTRACT
Objective To analyze the significance of cardiac enzymes and troponin in chronic kidney failure combined with acute left heart failure patients.Methods Thirty-eight chronic kidney failure combined with acute left heart failure patients were chosen as the experimental group,and 42 chronic kidney failure without acute left heart failure patients were chosen as the control group.The changes of creatine phosphokinase isoenzyme-MB (CK-MB),aspartic transaminase (AST),cardiac troponin Ⅰ (cTnI),creatinine were tested and compared.The prognosis of two groups was recorded.Results The level of CK-MB,cTnI in experimental group were significantly higher than those in control group [(36.23 ± 14.27) U/L vs.(14.71 ±8.27) U/L,(11.26 ± 5.04) μ g/L vs.(5.24 ± 2.31) μ g/L] (P ＜ 0.05).The level of AST,creatinine in two groups were higher than normal value,but there were no significant differences between two groups (P ＞0.05).The fatality rate in experimental group was significantly higher than that in control group [47.37％(18/38)vs.16.67％(7/42)](P＜ 0.01).Multiple stepwise regression analysis showed that CK-MB,cTnI were independent factors of prognosis (r =5.03,3.27,P ＜ 0.05).Conclusion The level of cardiac enzymes and troponin are important for the prognosis of chronic kidney failure combined with acute left heart failure patients.
ABSTRACT
Objective To investigate the association between body mass index (BMI) and exercise capacity in patients with chronic systolic heart failure.Methods The elderly patients with chronic systolic heart failure were consecutively recruited from 2008 to 2011 in cardiovascular clinic of Zhejiang Hospital.All the participants underwent height and weight measurements and BMI was calculated with these two parameters.Cardiopulmonary exercise test were performed to achieve peak oxygen uptake (PVO2),oxygen uptake to body mass ratio (PKVO2),oxygen uptake to heart ratio (VO2/HR) and ventilation/carbon dioxide production (VO2/VCO2).Results A total of the 273 patients with chronic systolic heart failure included 6 underweight patients (BMI ＜ 18.5 kg/m2),113 normal weight patients (BMI 18.5-＜ 24.0 kg/m2),116 overweight patients (BMI 24.0-＜ 28.0 kg/m2),and 38 obese patients (BMI ≥ 28 kg/m2).In both NYHA Ⅱ and Ⅲ/Ⅳ patients,unadjusted correlation analyses showed that BMI was positively related to PVO2 and VO2/HR,and was inversely related to PKVO2 and VE/VCO2 (P ＜ 0.05),respectively.Multiple stepwise regression analyses showed age,sex,BMI (P ＜ 0.05) and left ventricular ejection fraction (LVEF) were independent determinants of PKVO2,and age and BMI (P ＜ 0.05) were independent determinants of VE/VCO2.Conclusions BMI is significantly associated with exercise capacity in patients with chronic systolic heart failure,and also independent determinant for the PKVO2 and VE/VCO2,respectively.
ABSTRACT
FUNDAMENTO: A Hipertensão Arterial Sistêmica (HAS) é importante causa de Insuficiência Cardíaca sistólica Crônica (ICC) em países em desenvolvimento. Seria necessário conhecerem-se os fatores de predição de mortalidade para pacientes com essa condição clínica para melhor tratamento científico. OBJETIVO: Determinar os fatores de risco de mortalidade geral em pacientes com ICC secundária à HAS na era moderna do tratamento da ICC por disfunção sistólica do ventrículo esquerdo. MÉTODOS: Todos os pacientes rotineira e prospectivamente tratados na Clínica de Cardiomiopatia em nossa instituição de janeiro de 2000 a abril de 2008 com o diagnóstico de ICC secundária à HAS foram selecionados para o estudo. O modelo de riscos proporcionais de Cox foi utilizado para o estabelecimento de fatores de predição independentes de mortalidade geral. RESULTADOS: Cento e trinta pacientes foram estudados; 74 (57 por cento) eram homens. Trinta e um (24 por cento) pacientes faleceram; cinco (4 por cento) submeteram-se a transplante cardíaco; e 94 (72 por cento) estavam vivos ao final do estudo. A probabilidade de sobrevivência aos 12, 24, 36, 48 e 60 meses foi de 96 por cento, 93 por cento, 84 por cento, 79 por cento e 76 por cento, respectivamente. Idade (Razão de Riscos = 1,05, Intervalo de Confiança 95 por cento de 1,01 a 1,08, p = 0,01), dimensão diastólica do ventrículo esquerdo (Razão de Riscos = 1,08; Intervalo de Confiança 95 por cento de 1,02 a 1,09; p = 0,003) e terapia com betabloqueador (Razão de Riscos = 0,41; Intervalo de Confiança 95 por cento de 0,19 a 0,86; p = 0,02) foram os fatores de predição independentes de mortalidade geral. CONCLUSÃO: Idade, dimensão diastólica do ventrículo esquerdo e não uso de betabloqueador são fatores de predição independentes de mortalidade geral em pacientes com ICC sistólica secundária à HAS na população estudada.
BACKGROUND: Systemic arterial hypertension (SAH) is an important cause of chronic systolic heart failure (CHF) in underdeveloped countries. It would be desirable to know predictors of mortality for patients with this condition in order to provide proper scientific treatment. OBJECTIVE: To determine risk factors for all-cause mortality in patients with CHF secondary to SAH in the current era of heart failure therapy for left ventricular systolic dysfunction. METHODS: All patients routinely and prospectively followed at the Cardiomyopathy Clinic of our Institution from January, 2000 to April, 2008 with the diagnosis of CHF secondary to SAH were screened for the study. Cox proportional hazards model was used to establish independent predictors of all-cause mortality. RESULTS: One hundred thirty patients were included; 74 (57 percent) were male. Thirty one (24 percent) patients died, 5 (4 percent) underwent heart transplantation, and 94 (72 percent) were alive at study end. Survival probability at 12, 24, 36, 48, and 60 months was 96 percent, 93 percent, 84 percent, 79 percent, and 76 percent, respectively. Age (Hazard Ratio=1,05, 95 percent Confidence Interval 95 percent 1,01 to 1,08, p value=0,01), left ventricular diastolic dimension (Hazard Ratio=1,08; 95 percent Confidence Interval 1,02 to 1,09; p value=0,003), and B-Blocker therapy (Hazard Ratio=0,41; 95 percent Confidence Interval 0,19 to 0,86; p value=0,02) were found to be independent predictors of mortality. CONCLUSION: Age, left ventricular diastolic dimension and underuse of Beta-Blocker therapy were independent predictors of mortality for patients with CHF secondary to SAH in the population studied.
BUNDAMENTO: La Hipertensión Arterial Sistémica (HAS) es importante causa de Insuficiencia Cardíaca sistólica Crónica (ICC) en países en desarrollo. Sería necesario conocer los factores de predicción de mortalidad para pacientes con esa condición clínica para mejor tratamiento científico. OBJETIVO: Determinar los factores de riesgo de mortalidad general en pacientes con ICC secundaria a la HAS en la era moderna del tratamiento de la ICC por disfunción sistólica del ventrículo izquierdo MÉTODOS: Todos los pacientes rutinaria y prospectivamente tratados en la Clínica de Cardiomiopatía en nuestra institución de enero de 2000 a abril de 2008 con diagnóstico de ICC secundaria a la HAS fueron seleccionados para el estudio. El modelo de riesgos proporcionales de Cox fue utilizado para el establecimiento de factores de predicción independientes de mortalidad general. RESULTADOS: Ciento treinta pacientes fueron estudiados; 74 (57 por ciento) eran hombres. Treinta y un (24 por ciento) pacientes fallecieron; cinco (4 por ciento) se sometieron a transplante cardíaco; y 94 (72 por ciento) estaban vivos al final del estudio. La probabilidad de supervivencia a los 12, 24, 36, 48 y 60 meses fue de 96 por ciento, 93 por ciento, 84 por ciento, 79 por ciento y 76 por ciento, respectivamente. Edad (Razón de Riesgos = 1,05, Intervalo de Confianza 95 por ciento de 1,01 a 1,08, p = 0,01), dimensión diastólica del ventrículo izquierdo (Razón de Riesgos = 1,08; Intervalo de Confianza 95 por ciento de 1,02 a 1,09; p = 0,003) y terapia con betabloqueante (Razón de Riesgos = 0,41; Intervalo de Confianza 95 por ciento de 0,19 a 0,86; p = 0,02) fueron los factores de predicción independientes de mortalidad general. CONCLUSIÓN: Edad, dimensión diastólica del ventrículo izquierdo y no uso de betabloqueante son factores de predicción independientes de mortalidad general en pacientes con ICC sistólica secundaria a la HAS en la población estudiada.